Overview
Regulatory risk is a primary driver of deal value. We support venture capital, private equity, and pharma business development teams during M&A transactions. We assess the probability of regulatory success (PRS) and estimate the time and cost to approval.
Key Features
Probability of Success (POS) scoring
Timeline and cost modeling
Competitive regulatory landscape
Post-deal integration planning
Our Process
1
Diligence
Rapid review of the target asset.
2
Valuation
Inputting regulatory assumptions into the model.
3
Negotiation
Supporting deal terms based on findings.
Project Complete & Deliverables Provided
Frequently Asked Questions
PTRS (Probability of Technical and Regulatory Success) combines two factors: PTS (Probability of Technical Success—meeting clinical endpoints) and PRS (Probability of Regulatory Success—gaining approval). Industry-wide, only about 10% of Phase 1 drugs reach approval. We assess your specific asset against historical benchmarks, adjusting for therapeutic area, mechanism of action, clinical data quality, and regulatory pathway to estimate PTRS.
Why Choose Us
- Informed valuation models
- Risk-adjusted deal terms
- Smoother integration
- Avoidance of bad assets
Get More Details
Request a personalized consultation and detailed information about this service.
Personalized consultation
Detailed service information
Custom timeline & proposal
We'll respond within 24 hours
Ready to get started?
Contact our team to discuss your specific needs for M&A Support.
Schedule ConsultationWhat Our Clients Say
"We were about to close on a $400M acquisition when Adelphi's diligence uncovered a process validation failure that would delay approval by 18 months. We renegotiated the deal with milestone payments tied to FDA approval. That insight saved us from overpaying by $80M."
Michael Chen
Managing Partner
Healthcare-Focused PE Firm
Related Services
Explore other ways we can support your regulatory needs